ADIL - EXCLUSIVE: Adial Pharmaceuticals' Potential Treatment For Alcohol Use Disorder Shows Encouraging Safety Patient Compliance | Benzinga
Wednesday, Adial Pharmaceuticals Inc (NASDAQ:ADIL) announced the publication of a peer-reviewed article highlighting the clinical results, strong safety profile, and high compliance among patients administered AD04 (low-dose ondansetron).
AD04 is the company’s lead investigational new drug product being developed for the treatment of Alcohol Use Disorder (AUD).
The publication also reported the results of a new study analyzing the liver safety profile of AD04 compared with placebo in subjects with AUD in the company’s prior Phase 3 trial.
The published study provides a comprehensive analysis of the liver safety profile of AD04 compared to a placebo ...